Literature DB >> 29846835

Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.

Avner Thaler1,2,3,4, Efrat Kliper5, Inbal Maidan6,7,8, Talia Herman7, Keren Rosenberg-Katz5, Noa Bregman9, Tanya Gurevich6,10,11, Tamara Shiner10,11,9, Jeffrey M Hausdorff10,11,7, Avi Orr-Urtreger10,12, Nir Giladi6,10,11, Anat Mirelman10,8.   

Abstract

Cerebral atrophy has been detected in patients with Parkinson's disease (PD) both with and without dementia, however differentiation based on genetic status has thus far not yielded robust findings. We assessed cortical thickness and subcortical volumes in a cohort of PD patients and healthy controls carriers of the G2019S mutation in the LRRK2 gene and the common GBA mutations, in an attempt to determine whether genetic status influences structural indexes. Cortical thickness and subcortical volumes were computed and compared between six groups of participants; idiopathic PD, GBA-PD, LRRK2-PD, non-manifesting non-carriers (NMNC), GBA-non-manifesting carriers (NMC) and LRRK2-NMC utilizing the FreeSurfer software program. All participants were cognitively intact based on a computerized cognitive assessment battery. Fifty-seven idiopathic PD patients, 9 LRRK2-PD, 12 GBA-PD, 49 NMNC, 41 LRRK2-NMC and 14 GBA-NMC participated in this study. Lower volumes among patients with PD compared to unaffected participants were detected in bilateral hippocampus, nucleus accumbens, caudate, thalamus, putamen and amygdala and the right pallidum (p = 0.016). PD patients demonstrated lower cortical thickness indexes in a majority of regions assessed compared with non-manifesting participants. No differences in cortical thickness and subcortical volumes were detected within each of the groups of participants based on genetic status. Mutations in the GBA and LRRK2 genes are not important determinants of cortical thickness and subcortical volumes in both patients with PD and non-manifesting participants. PD is associated with a general reduction in cortical thickness and sub-cortical atrophy even in cognitively intact patients.

Entities:  

Keywords:  Cortical thickness; GBA; LRRK2; Parkinson’s disease; Sub-cortical volumes

Mesh:

Substances:

Year:  2018        PMID: 29846835     DOI: 10.1007/s10548-018-0653-8

Source DB:  PubMed          Journal:  Brain Topogr        ISSN: 0896-0267            Impact factor:   3.020


  7 in total

1.  Network abnormalities among non-manifesting Parkinson disease related LRRK2 mutation carriers.

Authors:  Yael Jacob; Keren Rosenberg-Katz; Tanya Gurevich; Rick C Helmich; Bastiaan R Bloem; Avi Orr-Urtreger; Nir Giladi; Anat Mirelman; Talma Hendler; Avner Thaler
Journal:  Hum Brain Mapp       Date:  2019-02-21       Impact factor: 5.038

Review 2.  Nucleus accumbens atrophy in Parkinson's disease (Mavridis' atrophy): 10 years later.

Authors:  Ioannis N Mavridis; Efstratios-Stylianos Pyrgelis
Journal:  Am J Neurodegener Dis       Date:  2022-06-20

3.  Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.

Authors:  Tanya Simuni; Liz Uribe; Hyunkeun Ryan Cho; Chelsea Caspell-Garcia; Christopher S Coffey; Andrew Siderowf; John Q Trojanowski; Leslie M Shaw; John Seibyl; Andrew Singleton; Arthur W Toga; Doug Galasko; Tatiana Foroud; Duygu Tosun; Kathleen Poston; Daniel Weintraub; Brit Mollenhauer; Caroline M Tanner; Karl Kieburtz; Lana M Chahine; Alyssa Reimer; Samantha J Hutten; Susan Bressman; Kenneth Marek
Journal:  Lancet Neurol       Date:  2019-10-31       Impact factor: 44.182

4.  DRD2 Taq1A Polymorphism-Related Brain Volume Changes in Parkinson's Disease: Voxel-Based Morphometry.

Authors:  Kenji Ohira; Hajime Yokota; Shigeki Hirano; Motoi Nishimura; Hiroki Mukai; Takuro Horikoshi; Setsu Sawai; Yoshitaka Yamanaka; Tatsuya Yamamoto; Shingo Kakeda; Satoshi Kuwabara; Tomoaki Tanaka; Takashi Uno
Journal:  Parkinsons Dis       Date:  2022-03-28

5.  Evaluating white matter alterations in Parkinson's disease-related parkin S/N167 mutation carriers using tract-based spatial statistics.

Authors:  Jinqiu Yu; Lina Chen; Guoen Cai; Yingqing Wang; Xiaochun Chen; Weimin Hong; Qinyong Ye
Journal:  Quant Imaging Med Surg       Date:  2022-08

Review 6.  Neuroimaging in Glucocerebrosidase-Associated Parkinsonism: A Systematic Review.

Authors:  Massimo Filippi; Roberta Balestrino; Silvia Basaia; Federica Agosta
Journal:  Mov Disord       Date:  2022-05-06       Impact factor: 9.698

Review 7.  Exploring the Genotype-Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers.

Authors:  Elisa Menozzi; Anthony H V Schapira
Journal:  Front Neurol       Date:  2021-06-24       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.